Legal & General Group
TARA icon

Legal & General Group’s Protara Therapeutics TARA Stock Holding History

Legal & General Group’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1K Hold
4,490
– – ﹤0.01% 3187
2026
Q1 		$23.4K Buy
4,490
+1,553
+53% +$9.19K ﹤0.01% 2912
2025
Q4 		$15.7K Hold
2,937
– – ﹤0.01% 3118
2025
Q3 		$12.8K Hold
2,937
– – ﹤0.01% 3220
2025
Q2 		$8.9K Buy
+2,937
New +$10.1K ﹤0.01% 3319
2021
Q2 		– Sell
-492
Closed -$8K – 3639
2021
Q1 		$8K Hold
492
– – ﹤0.01% 3437
2020
Q4 		$12K Buy
492
+186
+61% +$4.01K ﹤0.01% 3283
2020
Q3 		$5K Sell
306
-26
-8% -$603 ﹤0.01% 3383
2020
Q2 		$10K Buy
+332
New +$10.3K ﹤0.01% 3313

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Legal & General Group's TARA Position: Q2 2026 in Review

Legal & General Group held its Protara Therapeutics (TARA) position steady in Q2 2026 at 4,490 shares worth $17.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3187.

Legal & General Group first reported a position in TARA in Q2 2020 and has held it in 9 quarters since. The position peaked at $23.4K in Q1 2026. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Legal & General Group held 4,490 shares of Protara Therapeutics worth $17.1K as of Q2 2026.
  • Legal & General Group left its Protara Therapeutics share count unchanged in Q2 2026.
  • Protara Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3187 holding.
  • Legal & General Group first reported a position in Protara Therapeutics in Q2 2020 and has held it in 9 quarters since.
  • Legal & General Group's Protara Therapeutics position peaked at $23.4K in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.